Prilosec OTC Bioequivalence To Rx Version “Has No Impact” – P&G
This article was originally published in The Tan Sheet
Executive Summary
The lack of bioequivalence between Prilosec OTC (omeprazole) and Rx Prilosec is irrelevant to the product's OTC status because FDA approved the OTC version's toxicological profile as part of its review, Procter & Gamble maintains
You may also be interested in...
Prilosec OTC Patent Extension Submission Pending At PTO
AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity
Prilosec OTC Patent Extension Submission Pending At PTO
AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity
Prilosec OTC Patent Extension Submission Pending At PTO
AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity